BRAF突变型结直肠癌的治疗进展

Progress in treatment of BRAF mutant colorectal cancer

近年来,结直肠癌(CRC)的治疗取得了很大的进展,CRC患者整体生存率较前有了明显的提高,但raf鼠肉瘤滤过性病毒致癌基因同源体B1(BRAF)突变型CRC的疗效仍不尽如人意,BRAF突变患者较差的药物反应及预后仍是临床上的一大难题,至今BRAF突变型结直肠癌(BRAFmt CRC)的治疗方案仍未有明确定论,但近年来相关临床试验的开展为该类患者带来了更多治疗方案的选择及更好的疗效。

In recent years,great progress has been made in the treatment of colorectal cancer(CRC),and the overall survival rate of CRC patients has been significantly improved.However,the therapeutic effect of mutant CRC of V-raf murine sarcoma viral oncogene homolog B1(BRAF) is still unsatisfactory,and the poor drug response and prognosis of BRAF mutant patients are still a major clinical problem.Up to now,there is no definite conclusion on the treatment scheme of BRAF-mutant colorectal cancer(BRAFmt CRC).However,the development of relevant clinical trials in recent years has brought more choices of treatment schemes and better curative effects for such patients.